Valeant Pharmaceuticals International (NYSE:VRX) dropped by -5.26 or -1.34 points during the last session to $24.14 per share. One of the highlights of the day was the net money flow figure, which stood at $7.66 million even as the stock accepted $133.97 million in upticks but rejected $126.31 million in downticks. The up/down ratio for the last observation was a 1.06. The 1-week percentage change for the stock price is registered at -16.38%.A block transaction occurred with $9.66 million in upticks and $15.23 million in downticks while the up/down ratio was calculated to be 0.63. The stock witnessed a net inflow of $-5.57 million at the end of the block trade.
Currently the company Insiders own 8.62% of Valeant Pharmaceuticals International shares according to the proxy statements. Institutional Investors own 78.75% of Valeant Pharmaceuticals International shares. On the companys insider trading activities,The director officer (Chief Executive Officer) of Valeant Pharmaceuticals International, Inc., Pearson J. Michael sold 1,297,399 shares at $78.53 on November 5, 2015. The Insider selling transaction had a total value worth of $101,884,743. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Valeant Pharmaceuticals International (NYSE:VRX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.36 points or 1.49% at $23.78 with 23,690,637 shares getting traded. Post opening the session at $24.67, the shares hit an intraday low of $23.74 and an intraday high of $24.86 and the price was in this range throughout the day. The company has a market cap of $8,157 million and the number of outstanding shares have been calculated to be 343,030,280 shares. The 52-week high of Valeant Pharmaceuticals International (NYSE:VRX) is $263.81 and the 52-week low is $22.52.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Jefferies maintains its ratings on Valeant Pharmaceuticals International (NYSE:VRX). In the latest research report, Jefferies lowers the target price from $53 per share to $40 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 8, 2016.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.